$0.72
-0.04 (-5.52%)
Open$0.79
Previous Close$0.77
Day High$0.79
Day Low$0.70
52W High$1.35
52W Low$0.65
Volume—
Avg Volume78.2K
Market Cap26.31M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,407.0% upside
Current
$0.72
$0.72
Target
$32.64
$32.64
$20.70
$32.64 avg
$34.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.44M | 3.38M | 4.58M |
| Net Income | -8,199,231 | -7,249,541 | -1,151,647 |
| Profit Margin | -238.3% | -226.4% | -25.2% |
| EBITDA | -7,955,833 | -7,425,131 | -1,556,423 |
| Free Cash Flow | — | — | -1,101,967 |
| Rev Growth | +1.8% | +1.8% | +24.2% |
| Debt/Equity | 4.08 | 4.08 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |